Open Calls for Input and Feedback

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

Emgality (galcanezumab)

Therapeutic Area: Prevention of migraine
Draft recommendations posted for stakeholder feedback: November 18, 2021
End of feedback period: December 2, 2021
Draft Recommendation

Submit Feedback

Myinfla (colchicine)

Therapeutic Area: Atherothrombotic events in coronary artery disease
Draft recommendations posted for stakeholder feedback: November 18, 2021
End of feedback period: December 2, 2021
Draft Recommendation

Submit Feedback

Ngenla (somatrogon)

Therapeutic Area: Growth hormone deficiency
Draft recommendations posted for stakeholder feedback: November 18, 2021
End of feedback period: December 2, 2021
Draft Recommendation

Submit Feedback

Opsynvi (macitentan and tadalafil)

Therapeutic Area: Pulmonary arterial hypertension
Draft recommendations posted for stakeholder feedback: November 18, 2021
End of feedback period: December 2, 2021
Draft Recommendation

Submit Feedback

Open Calls for Patient and Clinician Input